WNT1: A Key Regulator in Osteogenesis and Neurodevelopment
Comprehensive genomic and functional analysis of the WNT1 gene, its role in bone density disorders and cancer, and clinical implications.
Gene Information Card
| Symbol | WNT1 |
|---|---|
| Full Name | Wnt family member 1 |
| Gene Type | protein-coding |
| Chromosomal Location | 12q13.12 |
| NCBI Gene ID | 7471 ncbi.nlm.nih.gov/gene/7471 |
| Ensembl ID | ENSG00000125084 |
| UniProt ID | P04628 |
| OMIM ID | 164820 |
| HGNC ID | 12765 |
| Aliases | INT1, OI15, BMND16 |
Description
WNT1 (Wnt family member 1) encodes a secreted signaling glycoprotein that is a member of the WNT gene family. It plays a critical role in embryonic development, particularly in the formation of the neural tube and the midbrain. In adults, WNT1 is essential for bone homeostasis by promoting osteoblast differentiation and bone formation. Mutations in WNT1 cause autosomal recessive osteogenesis imperfecta type XV and early-onset osteoporosis. Aberrant WNT1 signaling is also implicated in various cancers, including breast and lung cancer.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Osteogenesis imperfecta type XV | Loss-of-function mutations impair Wnt signaling in osteoblasts, leading to reduced bone formation and severe skeletal fragility. | OMIM #615220; ClinVar |
| Early-onset osteoporosis | Heterozygous or homozygous WNT1 mutations disrupt bone density regulation, causing low bone mass and fractures. | OMIM #615221; ClinVar |
| Breast cancer | WNT1 acts as an oncogene; overexpression activates canonical Wnt/β-catenin pathway, promoting cell proliferation and tumorigenesis. | COSMIC; PubMed studies |
| Lung cancer | WNT1 signaling contributes to epithelial-mesenchymal transition and metastasis. | COSMIC; PubMed studies |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Bone marrow | 0.0 | Not detected |
| Brain (cerebellum) | 0.0 | Not detected |
| Breast | 0.0 | Not detected |
| Lung | 0.0 | Not detected |
| Testis | 0.0 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 0.0 | No detectable expression in standard RNA-seq; low expression in some sublines |
| A549 (lung cancer) | 0.0 | Not detected |
| HEK293 (embryonic kidney) | 0.0 | Not detected |
| hFOB 1.19 (osteoblast) | 0.0 | Not detected in standard conditions; induced during differentiation |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.677C>T (p.Pro226Leu) | Missense | Rare | Loss of function; associated with osteogenesis imperfecta |
| c.506G>A (p.Cys169Tyr) | Missense | Rare | Loss of function; impairs secretion and signaling |
| c.1A>G (p.Met1Val) | Start loss | Rare | Loss of function; no protein production |
| c.110T>C (p.Leu37Pro) | Missense | Rare | Loss of function; disrupts protein folding |
Mutation functional classification
Loss of Function (LOF)
Most WNT1 mutations in osteogenesis imperfecta and osteoporosis are loss-of-function, reducing or abolishing Wnt signaling in osteoblasts.
Gain of Function (GOF)
Gain-of-function mutations are rare; overexpression in cancer is often due to epigenetic or transcriptional upregulation rather than somatic mutation.
Dominant Negative (DN)
Some missense mutations may exert dominant-negative effects by forming non-functional complexes with wild-type WNT1 or other Wnt proteins.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Wnt signaling pathway (KEGG hsa04310)
• Signaling by WNT (Reactome R-HSA-195721)
• Beta-catenin independent WNT signaling (Reactome R-HSA-3858494)
• Osteoblast differentiation (Reactome R-HSA-8940973)
Protein Summary
WNT1 is a 370-amino-acid secreted glycoprotein with a signal peptide, a conserved Wnt domain, and multiple cysteine residues critical for proper folding and function. It binds to Frizzled receptors and LRP5/6 co-receptors to activate the canonical Wnt/β-catenin pathway, leading to transcription of target genes involved in cell proliferation, differentiation, and bone formation. Post-translational modifications include glycosylation and palmitoylation, which are essential for secretion and receptor binding.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| WNT1 Knockout HEK293 Cell Line | EDJ-KQ118 | Human | 7471 | Details Get a Quote |
| WNT10A Knockout HEK293 Cell Line | EDJ-KQ347 | Human | 80326 | Details Get a Quote |
| WNT10B Knockout HEK293 Cell Line | EDJ-KQ348 | Human | 7480 | Details Get a Quote |
| WNT16 Knockout HEK293 Cell Line | EDJ-KQ349 | Human | 51384 | Details Get a Quote |
| WNT11 Knockout HEK293 Cell Line | EDJ-KQ1188 | Human | 7481 | Details Get a Quote |
| WNT10B Knockout A-549 Cell Line | EDJ-KQ18529 | Human | 7480 | Details Get a Quote |
| WNT10B Knockout HCT 116 Cell Line | EDJ-KQ18530 | Human | 7480 | Details Get a Quote |
| WNT10B Knockout HeLa Cell Line | EDJ-KQ18531 | Human | 7480 | Details Get a Quote |
| WNT16 Knockout HCT 116 Cell Line | EDJ-KQ18532 | Human | 51384 | Details Get a Quote |
| WNT1 Knockout HeLa Cell Line | EDJ-KQ54749 | Human | 7471 | Details Get a Quote |
| WNT11 Knockout HeLa Cell Line | EDJ-KQ54755 | Human | 7481 | Details Get a Quote |
| WNT16 Knockout HeLa Cell Line | EDJ-KQ56304 | Human | 51384 | Details Get a Quote |
| WNT10A Knockout HeLa Cell Line | EDJ-KQ57327 | Human | 80326 | Details Get a Quote |
| WNT1 Knockout A-549 Cell Line | EDJ-KQ63243 | Human | 7471 | Details Get a Quote |
| WNT11 Knockout A-549 Cell Line | EDJ-KQ63250 | Human | 7481 | Details Get a Quote |
Displaying Records 1 To 15 Of 20 Records